use
film
situ
zymographi
fiz
techniqu
demonstr
n
n
lleucyl
agmatin
inhibit
fasciola
hepatica
proteolyt
activ
vivo
aim
studi
establish
doserespons
relationship
inhibit
proteolysi
assess
fiz
differ
dosag
murin
model
fasciolosi
maximum
effect
inhibit
proteolysi
achiev
mgkgday
mice
treat
dose
surviv
mean
day
untreat
control
ova
count
egg
viabil
significantli
p
lower
latter
group
result
indic
intraperiton
administr
inhibit
liver
proteolyt
activ
dosedepend
manner
also
produc
antifecund
antiembryon
effect
delay
progress
fasciolosi
yet
residu
proteolysi
may
suggest
enzym
involv
chemic
interact
capabl
partial
agonisticlik
effect
fasciola
hepatica
infect
cattl
sheep
caus
signific
econom
loss
berasain
et
al
present
number
drug
treatment
fasciolosi
avail
yet
resist
strain
emerg
exampl
reduc
efficaci
identifi
closantel
triclabendazol
mulcahi
dalton
henc
alway
need
new
chemotherapeut
agent
trematod
speci
cystein
proteas
f
hepatica
repres
attract
target
chemotherapi
develop
enzym
play
key
role
life
cycl
parasit
evas
hostdefens
mechan
carmona
et
al
tissu
invas
dalton
heffernan
berasain
et
al
feed
yamasaki
et
al
smith
et
al
egg
output
dalton
et
al
incub
f
hepatica
metabol
product
lowmolecularweight
inhibitor
abolish
thiol
proteas
activ
dalton
heffernan
furthermor
recent
evalu
f
hepaticaproteolyt
activ
vivo
use
film
situ
zymographi
fiz
demonstr
liver
fluke
cystein
proteas
activ
inhibit
intraperiton
administr
dose
mgkg
bogyo
person
commun
n
n
lleucyl
agmatin
et
al
nonetheless
highest
possibl
efficaci
inhibit
f
hepatica
proteolyt
activ
antif
hepatica
effect
recognit
side
effect
teratogen
effect
earli
rat
embryogenesi
tachikura
remain
establish
anim
model
therefor
doserespons
relationship
assess
variabl
establish
evalu
antif
hepatica
efficaci
intraperiton
administ
cystein
proteas
inhibitor
murin
model
fasciolosi
use
wildtyp
mice
g
bodi
weight
free
f
hepatica
infect
confirm
coproparasitoscop
studi
use
experi
mice
hous
cage
temperaturecontrol
anim
room
allow
free
access
water
fed
standard
rodent
diet
rodent
lab
chow
purina
metacercaria
f
hepatica
obtain
infect
lymnaea
cubensi
snail
describ
vera
cystein
proteas
inhibitor
n
n
lleucyl
agmatin
sigma
dissolv
dimethyl
sulfoxid
dmso
final
concentr
adjust
distil
steril
water
one
mice
belong
infect
group
receiv
oral
metacercaria
suspens
group
six
mice
establish
seven
group
infect
f
hepatica
six
treat
day
intraperiton
volum
follow
mgkg
seventh
group
regard
control
treat
similar
volum
vehicl
remain
seven
group
infect
equal
treat
also
control
group
treat
vehicl
well
infect
group
inhibitor
administ
first
day
h
experiment
infect
h
thereaft
redos
carri
daili
week
anim
monitor
visual
evid
chang
day
time
survivor
euthan
order
estim
possibl
side
effect
mous
liver
sampl
anim
embed
paraffin
use
standard
techniqu
section
stain
haematoxylineosin
liver
section
compar
untreat
control
assess
proteolyt
activ
f
hepatica
cathepsin
three
liver
section
mous
analyz
fiz
previous
describ
et
al
brief
section
fresh
mice
liver
tissu
embed
cryomold
oct
tissuetek
mile
elkhart
frozen
dri
ice
frozen
section
dip
ntb
photograph
emuls
eastman
kodak
ny
gelatin
substrat
section
incub
humidifi
chamber
fh
incub
fig
doserespons
inhibit
situ
gelatinolyt
activ
f
hepatica
cystein
proteas
wt
mice
exert
intraperiton
inject
proteolyt
activ
observ
white
spot
dark
background
proteolysi
liver
section
f
hepaticainfect
mice
treat
vehicl
alon
b
reduct
gelatinolyt
activ
infect
mice
treat
mgkg
c
decreas
gelatinolyt
activ
liver
infect
mice
treat
mgkg
reduct
gelatinolyt
activ
liver
f
hepaticainfect
mice
treat
mgkg
e
inhibit
gelatin
degrad
hepat
tissu
mice
infect
treat
mgkg
f
decreas
proteolyt
activ
f
hepatica
proteas
liver
mice
treat
mgkg
g
inhibit
proteolysi
hepat
section
infect
mice
treat
mgkg
slide
airdri
develop
photograph
process
carri
proteolyt
activ
assess
use
light
microscopi
olympu
camera
pm
ak
japan
white
spot
dark
background
photograph
scan
hewlettpackard
scanjet
photosmart
scanner
situ
gelatinolysi
imag
analyz
use
imag
j
softwar
nation
institut
health
usa
fiz
imag
statist
analyz
mean
chisquar
test
perform
microsoft
offic
excel
microsoft
gall
bladder
mice
dissect
egg
recov
count
decant
bile
five
wash
egg
incub
day
dalton
et
al
period
egg
observ
order
estim
percentag
miracidi
develop
antifecund
efficaci
assess
reduct
egg
count
treatment
accord
vera
et
al
data
report
deviat
n
separ
experi
differ
group
determin
analysi
varianc
anova
student
test
bland
bonferroni
multipl
comparison
test
perneg
anova
conduct
use
sa
program
releas
sa
student
test
bonferroni
test
tabul
microsoft
offic
excel
microsoft
use
window
xp
oper
system
doserespons
relationship
inhibit
proteolysi
plot
fit
data
sigmoid
doserespons
curv
origin
originlab
doserespons
inhibit
f
hepatica
proteolyt
activ
reveal
fiz
proteolysi
detect
hepat
tissu
untreat
dmsotreat
mice
infect
f
hepatica
inhibit
liver
mice
treat
dose
low
mgkg
gelatin
degrad
treatment
group
significantli
decreas
respect
compar
nontreat
group
p
fig
respons
dose
statist
similar
mgkg
higher
dose
produc
inhibit
best
fit
obtain
sigmoid
regress
analysi
dose
mgkgday
emerg
lowest
dose
highest
efficaci
fig
surviv
time
variou
group
present
pattern
anim
treat
intraperiton
daili
mgkg
mgkg
mgkg
mgkg
surviv
mean
day
infect
wherea
mice
treat
mgkg
mgkg
surviv
mean
day
statist
signific
differ
surviv
time
obtain
latter
group
correspond
valu
former
one
p
untreat
control
surviv
mean
day
result
statist
differ
one
determin
mice
given
mgkg
higher
dose
p
evid
side
effect
could
attribut
seen
even
dose
mgkgday
howev
anim
treat
mgkgday
becam
letharg
examin
uninfectedtr
liver
slide
histolog
chang
could
link
drug
seen
egg
count
doserel
trend
also
notic
mean
decreas
number
egg
collect
gall
bladder
observ
infect
mice
given
mgkg
wherea
antifecund
efficaci
treatment
group
respect
statist
signific
differ
obtain
two
group
p
signific
p
reduct
also
observ
latter
group
correspond
valu
group
dose
mgkg
p
also
statist
signific
decreas
ova
count
group
given
mgkg
compar
untreat
control
p
egg
collect
treatment
group
fail
embryon
respect
comparison
ova
treatment
group
develop
miracidia
respect
signific
decreas
p
observ
group
given
mgkg
compar
two
treatment
group
statist
signific
differ
well
determin
among
mgkg
treatment
group
untreat
control
develop
miracidia
p
intraperiton
administr
mgkgday
lowest
possibl
dose
capabl
show
highest
antiproteolyt
effect
liver
f
hepaticainfect
mice
also
effect
delay
progress
murin
model
fasciolosi
yet
regress
analysi
suggest
dose
mgkg
lowest
dose
highest
efficaci
upon
vivo
evalu
higher
dose
unabl
improv
paramet
set
dose
inabl
reach
inhibit
proteolyt
activ
compli
well
find
hashida
et
al
report
intraperiton
inject
rat
inhibit
cathepsin
b
activ
certain
extent
higher
dose
appli
inhibit
observ
suggest
incorpor
cytosol
free
form
transport
lysosom
bind
cystein
proteas
previous
shown
diagnost
tool
studi
cystein
proteas
also
propos
possibl
therapeut
agent
due
potent
inhibitori
activ
stabil
permeabl
cell
tissu
power
et
al
exampl
administr
reduc
proteinuria
experiment
model
glomerulonephr
rat
barico
et
al
effect
also
test
resorpt
activ
osteoclast
delaiss
et
al
analogu
also
employ
biolog
studi
associ
attenu
prolifer
parathyroid
hormon
osteoblast
murray
et
al
inhibit
coronaviru
protein
process
rna
synthesi
kim
et
al
well
sever
biolog
process
power
et
al
use
fiz
describ
current
studi
consid
inhibit
specif
cystein
proteas
katunuma
kominami
note
gelatinolyt
activ
murin
model
fasciolosi
due
mainli
enzym
nevertheless
incomplet
reduct
gelatinolyt
activ
observ
liver
section
mice
postul
gelatinolysi
may
caus
proteas
cystein
proteas
yet
may
also
occur
proteolysi
due
cystein
proteas
might
total
inhibit
partial
inabl
fulli
interact
modifi
catalyt
domain
particular
f
hepatica
enzym
dose
mgkgday
clearli
delay
progress
fasciolosi
mice
live
lethal
infect
induc
mean
almost
day
infect
untreat
mice
result
may
therefor
taken
indic
cystein
proteas
activ
involv
tissu
invas
f
hepatica
suggest
previou
work
et
al
seem
close
relationship
rate
proteolysi
cours
infect
show
cystein
proteas
import
factor
vivo
patholog
effect
parasit
fact
strongli
inhibit
proteolysi
caus
f
hepatica
liver
encourag
find
mortal
due
fasciolosi
sheep
direct
consequ
liver
patholog
caus
migrat
fluke
dalton
et
al
interest
emphas
also
reduc
egg
product
hatch
abil
parasit
signific
p
decreas
ova
count
observ
treatment
group
compar
count
untreat
group
moreov
egg
group
failur
embryon
exact
mechan
affect
fluke
fecund
egg
viabil
known
tempt
specul
affect
egg
product
viabil
result
lack
nutrient
acquisit
liver
fluke
dalton
et
al
suggest
antibodi
produc
versu
cathepsin
l
proteas
may
block
cathepsin
l
activ
limit
parasit
feed
thu
prevent
amino
acid
intak
subsequ
synthesi
egg
protein
vaccin
sheep
cystein
proteas
f
hepatica
reduc
worm
fecund
egg
viabil
wijffel
et
al
best
knowledg
trial
describ
first
time
situ
proteolyt
activ
relat
worm
fecund
egg
viabil
fasciolosi
effect
drug
capabl
inhibit
liver
proteolysi
mean
decreas
embryon
egg
reduct
ova
count
experiment
dose
mgkgday
analysi
doserespons
relationship
yield
maximum
effect
dose
mgkgday
efficaci
link
hepat
injuri
nevertheless
frequent
dose
requir
order
achiev
optim
antif
hepatica
proteolysi
liver
henc
pharmaceut
design
requir
obtain
sustain
releas
formul
allow
nondaili
intraperiton
administr
summari
reason
suggest
cystein
proteas
f
hepatica
remain
promis
target
develop
chemotherapeut
agent
administr
togeth
tradit
therapi
includ
immunoprophylaxi
may
improv
clinic
outcom
